Gut

Article	Citations
Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19	809
Mucus barrier, mucins and gut microbiota: the expected slimy partners?	725
Gut microbiome and health: mechanistic insights	711
Gut microbiota-derived metabolites as central regulators in metabolic disorders	527
Interaction between drugs and the gut microbiome	449
Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report	415
Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites	392
Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN	351
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort	302
Global burden of oesophageal and gastric cancer by histology and subsite in 2018	297
Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome	285
Gut microbiome stability and resilience: elucidating the response to perturbations in order to modulate gut health	278
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases	252
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome	251
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus	241
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals	238
Effect of IBD medications on COVID-19 outcomes: results from an international registry	221
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome	214
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD	201
Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19	197
The role of gut microbiota in cancer treatment: friend or foe?	194
Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis	189
Impact of the COVID-19 pandemic on UK endoscopic activity and cancer detection: a National Endoscopy Database Analysis	188
Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) imm	183
Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study	176

Calprotectin: from biomarker to biological function	172
Guidelines on the management of ascites in cirrhosis	171
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology	169
SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting	166
Alterations in the human oral and gut microbiomes and lipidomics in COVID-19	165
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial	165
Helicobacter pyloriresistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community	161
Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing	155
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores	152
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort	151
Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching	151
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis	150
Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups	146
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab	144
Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning	144
European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients	141
Gut microbiota regulate Alzheimer’s disease pathologies and cognitive disorders via PUFA-associated neuroinflammation	134
Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide	131
F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer	128
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease	128
Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn	127
Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study	126
Diet quality and risk and severity of COVID-19: a prospective cohort study	126
Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies	125
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges	123
Six-month follow-up of gut microbiota richness in patients with COVID-19	122
Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial	121
COVID-19 in an international European liver transplant recipient cohort	114
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade	113
A faecal microbiota signature with high specificity for pancreatic cancer	112
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis	112
Human milk oligosaccharide DSLNT and gut microbiome in preterm infants predicts necrotising enterocolitis	111
Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic	109
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?	107
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives	107
Metabolic syndrome, metabolic comorbid conditions and risk of early-onset colorectal cancer	106
Artificial intelligence and colonoscopy experience: lessons from two randomised trials	105
Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma	103
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19	103
Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19	103
Faecal immunochemical test is superior to symptoms in predicting pathology in patients with suspected colorectal cancer symptoms referred on a 2WW pathway: a diagnostic accuracy study	101
Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort	100
Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16	100
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma	100
Bacteria-derived long chain fatty acid exhibits anti-inflammatory properties in colitis	100
Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies	99
Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure	99
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series	99
Recent advances in clinical practice: epidemiology of autoimmune liver diseases	97
Lactobacillus gallinarummodulates the gut microbiota and produces anti-cancer metabolites to protect against colorectal tumourigenesis	97

Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning	95
Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic func	93
Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury	93
British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults	93
Disrupted spermatogenesis in a metabolic syndrome model: the role of vitamin A metabolism in the gut–testis axis	93
Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women	93
Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice	92
Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites	92
Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis	90
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies	90
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism	90
Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population	90
Current therapies and new developments in NASH	89
Novel therapeutic targets for cholestatic and fatty liver disease	89
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification	89
Angiogenin maintains gut microbe homeostasis by balancing α-Proteobacteria and Lachnospiraceae	89
Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment	88
Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes	85
Gut microbiota composition is associated with SARS-CoV-2 vaccine immunogenicity and adverse events	84
Blue poo: impact of gut transit time on the gut microbiome using a novel marker	84
Targeting the gut-liver-immune axis to treat cirrhosis	83
Machine learning in GI endoscopy: practical guidance in how to interpret a novel field	81
Long-term yield of pancreatic cancer surveillance in high-risk individuals	81
Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett’s oesophagus and provides insights into clinical heterogeneity in reflux d	80
Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods	80
Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts	80
Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: a 24-week, double-blind, randomised controlled trial	79
Involvement of liver in COVID-19: systematic review and meta-analysis	78
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis	78
Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity	78
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom	77
Liquid biopsy in the clinical management of hepatocellular carcinoma	76
ABC score: a new risk score that accurately predicts mortality in acute upper and lower gastrointestinal bleeding: an international multicentre study	75
Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis	75
High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39+CD8+ T cells	74
MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis	73
Colon and rectal cancer survival in seven high-income countries 2010–2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)	72
Loss of hepatic Mboat7 leads to liver fibrosis	72
Estimating the environmental impact of disposable endoscopic equipment and endoscopes	72
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future	70
Advancing human gut microbiota research by considering gut transit time	69
Western-type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate	67
Prediction model of bleeding after endoscopic submucosal dissection for early gastric cancer: BEST-J score	67
Chinese Consensus Report on Family-BasedHelicobacter pyloriInfection Control and Management (2021 Edition)	67
Gastric per-oral endoscopic myotomy (G-POEM) for refractory gastroparesis: results from an international prospective trial	67
Utilisation of artificial intelligence for the development of an EUS-convolutional neural network model trained to enhance the diagnosis of autoimmune pancreatitis	67
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update	66
Critical thresholds: key to unlocking the door to the prevention and specific treatments for acute pancreatitis	65
Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers	65
ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1–TFAM signalling in alcoholic steatohepatitis	65
Faecal microbiota transplantation with anti-inflammatory diet (FMT-AID) followed by anti-inflammatory diet alone is effective in inducing and maintaining remission over 1 year in mild to moderate ulce	65
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial	64
CXCR2 inhibition enables NASH-HCC immunotherapy	64
Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder	64
Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis	64
Bidirectional brain–gut axis effects influence mood and prognosis in IBD: a systematic review and meta-analysis	63
RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer	61
Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet	61
Mass eradication ofHelicobacter pylorito reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands	60
SARS-CoV-2 infection in acute pancreatitis increases disease severity and 30-day mortality: COVID PAN collaborative study	60
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea	60
Long-term outcomes after endoscopic treatment for Barrett’s neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period	60
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer	60
Human and preclinical studies of the host–gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health	59
Proton pump inhibitors and risk of gastric cancer: population-based cohort study	59
Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database	58
Location-specific cell identity rather than exposure to GI microbiota defines many innate immune signalling cascades in the gut epithelium	58
Equivalent performance of single-use and reusable duodenoscopes in a randomised trial	58
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade	57
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease	57
Recent advances in clinical practice: colorectal cancer chemoprevention in the average-risk population	57
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma	56
Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance	56
PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF	56
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size	56
Niche-specific functional heterogeneity of intestinal resident macrophages	56
Interplay between diet and gut microbiome, and circulating concentrations of trimethylamine N-oxide: findings from a longitudinal cohort of US men	55
Deconvolution of monocyte responses in inflammatory bowel disease reveals an IL-1 cytokine network that regulates IL-23 in genetic and acquired IL-10 resistance	55
FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2	55
Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment	55

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms	55
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis	55
British Society of Gastroenterology guidelines on the management of functional dyspepsia	55
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis	55
The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma	55
Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study	55
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)	54
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial	53
Dietary macronutrients and the gut microbiome: a precision nutrition approach to improve cardiometabolic health	53
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis	53
Multiomics analysis reveals the presence of a microbiome in the gut of fetal lambs	53
Methionine deficiency facilitates antitumour immunity by altering m6A methylation of immune checkpoint transcripts	53
Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis	53
Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study	53
Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study	52
Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism	52
Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny	51
Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy	50
Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes	50
Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation	50
Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers	50
Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world	49
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer	49
Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer	49
Oncogenetic landscape of lymphomagenesis in coeliac disease	49
COVID-19 and liver disease	49
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer	49
Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial	48
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases	48
Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links	47
Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression	47
Genomic evolution and diverse models of systemic metastases in colorectal cancer	47
Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions	46
Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma	46
Emerging treatment options for extraintestinal manifestations in IBD	46
Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health	46
Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease	45
PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicabil	45
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care	45
Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma	45
Organoids in gastrointestinal diseases: from experimental models to clinical translation	45
Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients	45
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study	44
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPG	44
From the origin of NASH to the future of metabolic fatty liver disease	44
Rapid resolution of COVID-19 after faecal microbiota transplantation	43
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial	43
Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies	43
Genetic architectures of proximal and distal colorectal cancer are partly distinct	43
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients	43
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS	42
Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease	42
Global prevalence of Barrett’s oesophagus and oesophageal cancer in individuals with gastro-oesophageal reflux: a systematic review and meta-analysis	41
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells	41
Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases	41
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection	40
GI symptoms as early signs of COVID-19 in hospitalised Italian patients	40
Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource	40
Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc–xCT	40
Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment	40
Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo	39
Safely restarting GI endoscopy in the era of COVID-19	39
Non-compliance with colonoscopy after a positive faecal immunochemical test doubles the risk of dying from colorectal cancer	39
NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis	39
SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation	39
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications	39
Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System	39
Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts	39
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model	38
6α-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice	38
Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer	38
One world, one pandemic, many guidelines: management of liver diseases during COVID-19	38
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa	38
Serotonin is elevated in COVID-19-associated diarrhoea	38
PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma	38
Stool microRNA profiles reflect different dietary and gut microbiome patterns in healthy individuals	37
Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease	37
Prostaglandin E2 receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation	37
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection	37
Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination	36
Rescue of male fertility following faecal microbiota transplantation from alginate oligosaccharide-dosed mice	36
Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry	36
Multicentre, prospective, randomised study comparing the diagnostic yield of colon capsule endoscopy versus CT colonography in a screening population (the TOPAZ study)	36
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds	36
Human gastric microbiota transplantation recapitulates premalignant lesions in germ-free mice	36
Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma	36
A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer	36
Large-scale, national, family-based epidemiological study onHelicobacter pyloriinfection in China: the time to change practice for related disease prevention	35
Gut as viral reservoir: lessons from gut viromes, HIV and COVID-19	35
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life	35
Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis	35
Depression in individuals who subsequently develop inflammatory bowel disease: a population-based nested case–control study	35
Proton pump inhibitors and the risk of severe COVID-19: a post-hoc analysis from the Korean nationwide cohort	35
Standalone performance of artificial intelligence for upper GI neoplasia: a meta-analysis	35
Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale	34